Durable natural killer cell responses after heterologous two-dose Ebola vaccination.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
29 Jan 2021
29 Jan 2021
Historique:
received:
21
07
2020
accepted:
04
01
2021
entrez:
30
1
2021
pubmed:
31
1
2021
medline:
31
1
2021
Statut:
epublish
Résumé
Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo (EBOVAC2 consortium, EU Innovative Medicines Initiative), induces NK cell activation and anti-Ebola glycoprotein (GP) antibody-dependent NK cell activation post-dose 1, which is further elevated post-dose 2. Here, in a multicentre, phase 2 clinical trial (EBL2001), we demonstrate durable ex vivo NK cell activation 180 days after dose 2, with responses enriched in CD56
Identifiants
pubmed: 33514756
doi: 10.1038/s41541-021-00280-0
pii: 10.1038/s41541-021-00280-0
pmc: PMC7846750
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Subventions
Organisme : Medical Research Council
ID : G1000808
Pays : United Kingdom
Références
J Virol Methods. 2018 May;255:84-90
pubmed: 29481881
J Immunol. 2016 Jul 1;197(1):313-25
pubmed: 27233958
JAMA. 2017 Mar 14;317(10):1075-1077
pubmed: 28291882
J Immunol. 2015 Oct 1;195(7):3262-72
pubmed: 26283480
Immunity. 2017 Nov 21;47(5):820-833
pubmed: 29166586
Hum Vaccin Immunother. 2017 Feb;13(2):266-270
pubmed: 27925844
Cell Host Microbe. 2018 Aug 8;24(2):221-233.e5
pubmed: 30092199
Blood. 2010 Nov 11;116(19):3853-64
pubmed: 20696944
J Immunol. 2012 May 15;188(10):5054-62
pubmed: 22504653
J Infect Dis. 2018 Nov 22;218(suppl_5):S504-S507
pubmed: 30060221
J Immunol. 2016 Aug 15;197(4):1100-1110
pubmed: 27412415
J Virol. 2014 Aug;88(15):8349-54
pubmed: 24829350
J Infect Dis. 2019 Dec 10;:
pubmed: 31821493
J Immunol. 2010 Sep 1;185(5):2808-18
pubmed: 20679529
Immunology. 2014 May;142(1):140-50
pubmed: 24843874
JAMA. 2016 Apr 19;315(15):1610-23
pubmed: 27092831
PLoS Pathog. 2014 Nov 20;10(11):e1004509
pubmed: 25412102
Sci Rep. 2017 Mar 30;7:45552
pubmed: 28358050
J Infect Dis. 2019 Jun 5;220(1):46-56
pubmed: 30796818
NPJ Vaccines. 2020 Apr 14;5:32
pubmed: 32337075
Cell Host Microbe. 2019 Jan 9;25(1):39-48.e5
pubmed: 30629917
Cell Host Microbe. 2019 Jan 9;25(1):49-58.e5
pubmed: 30629918
J Virol. 2010 Jan;84(1):27-33
pubmed: 19846529
J Clin Invest. 2020 Jul 1;130(7):3936-3946
pubmed: 32315287
Blood. 2014 Oct 2;124(14):2213-22
pubmed: 25150297
J Virol. 2018 May 14;92(11):
pubmed: 29514907
Blood. 2003 Apr 15;101(8):3052-7
pubmed: 12480696
Sci Rep. 2016 Jun 21;6:27944
pubmed: 27323685
Immunity. 2015 Mar 17;42(3):443-56
pubmed: 25786176
J Infect Dis. 2019 Jun 5;220(1):57-67
pubmed: 30796816
Immunity. 2015 Mar 17;42(3):431-42
pubmed: 25786175
Front Microbiol. 2017 Aug 17;8:1571
pubmed: 28861075
J Immunol. 2004 Feb 1;172(3):1455-62
pubmed: 14734722
Sci Immunol. 2016 Sep;1(3):
pubmed: 27868107
Front Immunol. 2016 Mar 22;7:101
pubmed: 27047490
J Immunol. 2011 Apr 15;186(8):4590-8
pubmed: 21402893